ArticleOncotarget2016

TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.

Jun-Chuang He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.